Pityriasis rosea following SARS‐CoV‐2 vaccination: A case series

Temiz, Selami Aykut; Abdelmaksoud, Ayman; Dursun, Recep; Durmaz, Koray; Sadoughifar, Roxanna; Hasan, Abdulkarim

doi:10.1111/jocd.14372

Cited by 26 publications

(33 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pityriasis rosea is a complication that appeared within 22 days and resolved within 12 weeks of vaccination [ 1 , 2 , 16 , 17 , 21 , 23 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 ]. It was associated with BNT162b2 vaccination in most patients (71.9%; 41 of 57 eruptions, Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer–BioNTech), and AZD1222 (AstraZeneca–Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.

show abstract

Section: Resultsmentioning

confidence: 99%

“…It was associated with BNT162b2 vaccination in most patients (71.9%; 41 of 57 eruptions, Table 1 ). In a series of 14 patients, the median onset was 14 days after the first vaccine dose and 9 days after the second [ 40 ]. In a cross-sectional study, pityriasis rosea-like eruption was the longest-lasting cutaneous reaction pattern [ 2 ].…”

Section: Resultsmentioning

confidence: 99%

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Recently, a case series of 31 patients with PR following COVID-19 vaccination revealed that 45.2% (14 cases) had received BNT162b2 mRNA vaccine, while 54.8% (17 cases) had received inactivated CoronaVac vaccine. 9 The average onset time was 12.7 days following vaccination, and patients recovered in 7.8 weeks on average after treatment with topical corticosteroids and oral antihistamines. Remarkably, a higher percentage of PR after inactivated COVID-19 vaccine injection was noted.…”

Section: Discussionmentioning

confidence: 99%

Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review

Wang

Chen

Liu

2022

Journal of the Formosan Medical Association

View full text Add to dashboard Cite

Pityriasis rosea (PR) is a self-limited disease with exanthematous papulosquamous rashes mostly associated with reactivation of human herpesvirus (HHV)-6 or HHV-7. PR-like eruptions, which occur along with peripheral eosinophilia, interface dermatitis, and eosinophils on histopathology, may result from medications or vaccinations. Previously, PR-like eruptions had been noted following vaccination for influenza or other vaccines. During this pandemic, acute COVID-19 infection has been related to PR or PR-like eruptions in several cases. Various COVID-19 vaccines associated with PR-like eruptions were rarely reported. Herein, we report a case of cutaneous PR-like eruptions following COVID-19 mRNA-1273 vaccination.

show abstract

“…To date, 5.5 billion vaccine doses have been administered [ 1 ]. The adverse effects of vaccines are mostly mild and transient, commonly including pain at the injection site, pyrexia, headache, myalgias, fatigue, chills [ 5 ] and dermatologic manifestations like Pityriasis Rosea [ 6 ]. However, severe complications like anaphylaxis [ 7 ], vaccine-induced immune thrombotic thrombocytopenia [ 8 ], myocarditis [ 9 ] have also been reported.…”

Section: Introductionmentioning

confidence: 99%

SARS-CoV-2 vaccine-associated-tinnitus: A review

Ahmed

Waseem

Shaikh

et al. 2022

Annals of Medicine &Amp; Surgery

View full text Add to dashboard Cite

The global vaccination drive against severe acute respiratory syndrome coronavirus-2 is being pursued at a historic pace. Unexpected adverse effects have been reported following vaccination, including thrombotic thrombocytopenia, myocarditis, amongst others. More recently, some cases of tinnitus are reported post-vaccination. According to the Vaccine Adverse Events Reporting System (VAERS), 12,247 cases of coronavirus post-vaccination tinnitus have been reported till 14 th September 2021. To the best of our knowledge, this is the first review evaluating any otologic manifestation following vaccine administration and aims to evaluate the potential pathophysiology, clinical approach, and treatment. Although the incidence is infrequent, there is a need to understand the precise mechanisms and treatment for vaccine-associated-tinnitus.

show abstract

Pityriasis rosea following SARS‐CoV‐2 vaccination: A case series

Cited by 26 publications

References 13 publications

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Cutaneous Complications of mRNA and AZD1222 COVID-19 Vaccines: A Worldwide Review

Pityriasis Rosea-like eruptions following COVID-19 mRNA-1273 vaccination: A case report and literature review

SARS-CoV-2 vaccine-associated-tinnitus: A review

Contact Info

Product

Resources

About